Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating
Buy Rating Affirmed for Immunocore Holdings on Strong Kimmtrak Performance and Market Dominance
Mizuho Securities Maintains Immunocore(IMCR.US) With Buy Rating
Immunocore Holdings: Outperform Rating With Promising Sales Growth and Strategic Advantages
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Express News | Immunocore : Mizuho Cuts Target Price to $72 From $88
Earnings Call: Immunocore Reports Robust Growth for KIMMTRAK in Q2
Mizuho Adjusts Immunocore Holdings' PT to $72 From $88, Keeps Outperform Rating
The Immunocore Holdings Plc (NASDAQ:IMCR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Immunocore Holdings Plc (IMCR) Q2 2024 Earnings Call Transcript
Immunocore Holdings Is Maintained at Overweight by Barclays
Express News | Immunocore : Oppenheimer Raises Target Price to $89 From $87
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
Immunocore Holdings (IMCR) Gets a Buy From BTIG
Express News | Immunocore Holdings PLC : Barclays Cuts Target Price to $66 From $92
Express News | Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Immunocore Hldgs Analyst Ratings
Express News | Immunocore : Jefferies Cuts Target Price to $70 From $90
Immunocore Holdings: Strong Kimmtrak Sales and Promising Pipeline Merit Buy Rating
Optimistic Buy Rating on Immunocore Holdings Amid Strong Kimmtrak Sales and Promising Oncology Pipeline